Ubs Group Ag Bio N Tech Se Put Options Transaction History

Ubs Group Ag

13 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$78.36 - $124.66 $7.55 Million - $12 Million	96,400 Added 135.97%	167,300 $19.9 Million
Q2 2024 Aug 13, 2024	BUY	$80.36 - $102.87 $2.62 Million - $3.35 Million	32,600 Added 85.12%	70,900 $5.7 Million
Q1 2024 May 13, 2024	SELL	$88.96 - $112.35 $1.05 Million - $1.33 Million	-11,800 Reduced 23.55%	38,300 $3.53 Million
Q4 2023 Feb 09, 2024	BUY	$90.91 - $112.75 $1.25 Million - $1.56 Million	13,800 Added 38.02%	50,100 $5.29 Million
Q3 2023 Nov 09, 2023	BUY	$98.5 - $125.08 $3.58 Million - $4.54 Million	36,300 New	36,300 $3.94 Million
Q1 2023 May 12, 2023	BUY	$122.57 - $153.67 $1.84 Million - $2.31 Million	15,000 Added 75.0%	35,000 $4.36 Million
Q4 2022 Feb 08, 2023	SELL	$118.43 - $186.05 $1.18 Million - $1.86 Million	-10,000 Reduced 33.33%	20,000 $3 Million
Q3 2022 Nov 10, 2022	BUY	$127.65 - $183.11 $3.83 Million - $5.49 Million	30,000 New	30,000 $4.05 Million
Q1 2022 May 16, 2022	SELL	$126.25 - $231.85 $26.3 Million - $48.2 Million	-208,000 Reduced 79.42%	53,900 $9.19 Million
Q4 2021 Feb 14, 2022	SELL	$216.64 - $362.52 $5.5 Million - $9.21 Million	-25,400 Reduced 8.84%	261,900 $67.5 Million
Q3 2021 Nov 15, 2021	BUY	$205.93 - $447.23 $679,569 - $1.48 Million	3,300 Added 1.16%	287,300 $78.4 Million
Q2 2021 Aug 13, 2021	BUY	$113.32 - $241.49 $15.2 Million - $32.4 Million	134,000 Added 89.33%	284,000 $63.6 Million
Q1 2021 May 12, 2021	BUY	$85.73 - $119.5 $12.9 Million - $17.9 Million	150,000 New	150,000 $16.4 Million

357

38.3M

2.45M

2.29M

Ticker BNTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 242,684,992
Market Cap $27.4B
Description
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.